The review found no eligible studies for this question.
It is very uncertain whether alemtuzumab 12 mg changes dropouts Assessed by: number of participants who dropped out compared with interferon beta‐1a (very low certainty).
Alemtuzumab 12 mg probably leads to lower number of participants experiencing at least one relapse compared with interferon beta 1a (moderate certainty).
Alemtuzumab 12 mg may leads to lower number of participants whose disability worsened compared with interferon beta 1a (low certainty).
Alemtuzumab 12 mg showed no clear difference in number of participants with at least one adverse event compared with interferon beta 1a (low certainty).
Alemtuzumab 12 mg showed no clear difference in number of participants with serious adverse events compared with interferon beta 1a (moderate certainty).
Alemtuzumab 12 mg may leads to lower number of participants with new T2‐hyperintense lesions on magnetic… compared with interferon beta 1a (low certainty).
Alemtuzumab 12 mg may leads to lower number of participants experiencing treatment discontinuation caused… compared with interferon beta 1a (low certainty).
Anti‐leukaemic therapy plus alemtuzumab probably leads to lower overall survival (median 2 years) compared with anti‐leukaemic therapy alone (anti‐leukaemic therapy identical (moderate certainty).
Anti‐leukaemic therapy plus alemtuzumab may leads to lower progression free survival (median 2 years) compared with anti‐leukaemic therapy alone (anti‐leukaemic therapy identical (low certainty).
Anti‐leukaemic therapy plus alemtuzumab showed no clear difference in treatment related mortality compared with anti‐leukaemic therapy alone (anti‐leukaemic therapy identical (moderate certainty).
Anti‐leukaemic therapy plus alemtuzumab leads to higher cytomegalovirus reactivation compared with anti‐leukaemic therapy alone (anti‐leukaemic therapy identical (high certainty).
Anti‐leukaemic therapy plus alemtuzumab may leads to higher complete response rate compared with anti‐leukaemic therapy alone (anti‐leukaemic therapy identical (low certainty).
Anti‐leukaemic therapy plus alemtuzumab may leads to higher infections (all grades) compared with anti‐leukaemic therapy alone (anti‐leukaemic therapy identical (low certainty).
Anti‐leukaemic therapy plus alemtuzumab showed no clear difference in serious adverse events compared with anti‐leukaemic therapy alone (anti‐leukaemic therapy identical (moderate certainty).
The intervention leads to lower alemtuzumab No direct evidence (high certainty).
The intervention may leads to lower alemtuzumab No direct evidence (low certainty).
The intervention probably leads to lower alemtuzumab No direct evidence (moderate certainty).
It is very uncertain whether the intervention changes alemtuzumab No direct evidence (very low certainty).